PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1400978
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1400978
Asia Pacific Complement-Targeted Therapeutics Market, By Indication, By Distribution Channel, By Route of Administration, and By Country - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
REPORT HIGHLIGHT
Asia Pacific Complement-Targeted Therapeutics Market size was valued at USD 1,810 Million in 2022, expanding at a CAGR of 10.6% from 2023 to 2030.
A key element of innate immunity that connects the innate and adaptive immune responses is complement-targeted therapy. It is implicated in a variety of illnesses and pathological states and can use its destructive powers against host cells. Many therapeutic modalities have been established because of the recognition of complement system modulation as a promising drug development technique.
Complement-Targeted Therapeutics Market- Market Dynamics
Growing awareness of complement-mediated disorders is expected to propel market demand
The growing awareness of complement-mediated illnesses and the benefits of therapies that target complement. The quick development of innovative, state-of-the-art complement-targeted medicines is driving growth in the global market for these treatments. Furthermore, both governmental and private investments in healthcare drive the market. The elderly are more likely to suffer from chronic ailments, which makes complement-targeted therapy more necessary. The market is also being driven ahead by the discovery of novel therapeutic targets because of research and technological improvements. The market is also being driven by the growing pipeline of newly developed drugs and the rising need for treatments for complement-mediated diseases.
Complement-Targeted Therapeutics Market- Key Insights
As per the analysis shared by our research analyst, the Asia Pacific market is estimated to grow annually at a CAGR of around 10.6% over the forecast period (2023-2030)
Based on Indication segmentation, Paroxysmal Nocturnal Haemoglobinuria segment was predicted to show maximum market share in the year 2022, The increasing demand for orthopedic implants treatment is boosting the market growth.
Based on Distribution Channel segmentation, hospital pharmacies was the leading market in 2022, due to increasing hospital pharmacies in distributing and dispensing these specialized drugs to patients suffering from complement-mediated diseases.
Based on Route of Administration segmentation, oral was the leading market in 2022, due to increasing demand from oral complement targeted drugs.
On the basis of country, India was the leading revenue generator in 2022 mainly due to the growing prevalence of chronic diseases.
Complement-Targeted Therapeutics Market- Segmentation Analysis:
The Asia Pacific Complement-Targeted Therapeutics Market is segmented on the basis of Indication, Distribution Channel, Route of Administration, and Region.
The market is divided into two categories based on Indication: Paroxysmal Nocturnal Haemoglobinuria, and Atypical Haemolytic Uraemic Syndrome. The Paroxysmal Nocturnal Haemoglobinuria segment dominates the market. The growing prevalence of illness, chronic diseases is contributing to segment growth.
The market is divided into three categories based on Distribution Channel: hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies dominate the market and is likely to maintain its dominance during the forecast period. The rising patients of cancer and autoimmune disorders, which has fueled the demand therapeutics is expected to boost the segmental growth.
The market is divided into three categories based on Route of Administration: oral, diagnostic tests, and others. The oral segment dominates the market and is likely to maintain its dominance during the forecast period. The growing demand for complement-targeted therapeutics for oral injectables is mainly boosting the market growth.
Complement-Targeted Therapeutics Market- Country Insights
Country wise, this market is widespread into India, China, South Korea, Japan, Australia, Thailand, Indonesia, Philippines, Malaysia, Taiwan, Vietnam, Hong Kong, New Zealand, Singapore, Myanmar, and the rest of the Asia-Pacific (APAC) region.
Complement-Targeted Therapeutics Market- Competitive Landscape:
The Asia Pacific market for Complement-Targeted Therapeutics is moderately competitive in nature. The prevalence of complement-mediated disorders rising, the presence of strong rivals in the market, and enhanced healthcare infrastructure. Furthermore, the region is seeing a variety of current research and development initiatives in complement medicines, which will ultimately lead to the region's expansion. Further, the companies are involved in partnering and collaborating with each other to develop new methods and enhance patient outcomes.
Recent Developments:
In November 2022, KORU Medical Systems, Inc., a well-known medical technology firm recognized for producing cutting-edge subcutaneous infusion solutions, extended its collaboration with Kira Pharmaceuticals. Kira will utilize KORU Medical's Freedom System in Phase II clinical trials of KP-104, a groundbreaking bifunctional complement inhibitor, for three therapeutic indications.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
ASIA PACIFIC COMPLEMENT-TARGETED THERAPEUTICS MARKET KEY PLAYERS
KORU Medical Systems, Inc
Vertex Pharmaceuticals
Alexion Pharmaceuticals Inc.
F. Hoffmann-La Roche Ltd.
Creative Biolabs
Biogen
Allergan
Sanofi
AbbVie Inc.
Merck and Co
Pfizer Inc.
Dianthus Therapies
Others
ASIA PACIFIC COMPLEMENT-TARGETED THERAPEUTICS MARKET, BY INDICATION
Paroxysmal Nocturnal Haemoglobinuria
Atypical Haemolytic Uraemic Syndrome
ASIA PACIFIC COMPLEMENT-TARGETED THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
ASIA PACIFIC COMPLEMENT-TARGETED THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
Oral
Diagnostic Tests
Others
ASIA PACIFIC COMPLEMENT-TARGETED THERAPEUTICS MARKET, BY REGION
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Malaysia
Taiwan
Vietnam
Hong Kong
New Zealand
Singapore
Myanmar
Rest of APAC
Table of Contents
1. Asia Pacific Complement-Targeted Therapeutics Market Overview
- 1.1. Study Scope
- 1.2. Market Estimation Years
2. Executive Summary
- 2.1. Market Snippet
- 2.1.1. Asia Pacific Complement-Targeted Therapeutics Market Snippet by Indication
- 2.1.2. Asia Pacific Complement-Targeted Therapeutics Market Snippet by Distribution Channel
- 2.1.3. Asia Pacific Complement-Targeted Therapeutics Market Snippet by Route of Administration
- 2.1.4. Asia Pacific Complement-Targeted Therapeutics Market Snippet by Country
- 2.1.5. Asia Pacific Complement-Targeted Therapeutics Market Snippet by Region
- 2.2. Competitive Insights
3. Complement-Targeted Therapeutics Key Market Trends
- 3.1. Asia Pacific Complement-Targeted Therapeutics Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
- 3.2. Asia Pacific Complement-Targeted Therapeutics Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
- 3.3. Asia Pacific Complement-Targeted Therapeutics Market Opportunities
- 3.4. Asia Pacific Complement-Targeted Therapeutics Market Future Trends
4. Complement-Targeted Therapeutics Industry Study
- 4.1. PEST Analysis
- 4.2. Porter's Five Forces Analysis
- 4.3. Growth Prospect Mapping
- 4.4. Regulatory Framework Analysis
5. Asia Pacific Complement-Targeted Therapeutics Market: COVID-19 Impact Analysis
- 5.1. Pre-COVID-19 Impact Analysis
- 5.2. Post-COVID-19 Impact Analysis
- 5.2.1. Top Performing Segments
- 5.2.2. Marginal Growth Segments
- 5.2.3. Top Looser Segments
- 5.2.4. Marginal Loss Segments
6. Asia Pacific Complement-Targeted Therapeutics Market Landscape
- 6.1. Asia Pacific Complement-Targeted Therapeutics Market Share Analysis, 2022
- 6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis
7. Asia Pacific Complement-Targeted Therapeutics Market - By Indication
- 7.1. Overview
- 7.1.1. Segment Share Analysis, By Indication, 2022 & 2030 (%)
- 7.1.2. Paroxysmal Nocturnal Haemoglobinuria
- 7.1.3. Atypical Haemolytic Uraemic Syndrome
8. Asia Pacific Complement-Targeted Therapeutics Market - By Distribution Channel
- 8.1. Overview
- 8.1.1. Segment Share Analysis, By Distribution Channel, 2022 & 2030 (%)
- 8.1.2. Hospital Pharmacies
- 8.1.3. Retail Pharmacies
- 8.1.4. Online Pharmacies
9. Asia Pacific Complement-Targeted Therapeutics Market - By Route of Administration
- 9.1. Overview
- 9.1.1. Segment Share Analysis, By Route of Administration, 2022 & 2030 (%)
- 9.1.2. Oral
- 9.1.3. Diagnostic Tests
- 9.1.4. Others
10. Asia Pacific Complement-Targeted Therapeutics Market- By Country
- 10.1. Introduction
- 10.1.1. Segment Share Analysis, By Country, 2022 & 2030 (%)
- 10.2. Asia Pacific
- 10.2.1. Overview
- 10.2.2. Complement-Targeted Therapeutics Key Manufacturers in Asia Pacific
- 10.2.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
- 10.2.4. Asia Pacific Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
- 10.2.5. Asia Pacific Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 10.2.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
- 10.2.7. India
- 10.2.7.1. Overview
- 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 10.2.7.3. India Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
- 10.2.7.4. India Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 10.2.7.5. India Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
- 10.2.8. China
- 10.2.8.1. Overview
- 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 10.2.8.3. China Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
- 10.2.8.4. China Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 10.2.8.5. China Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
- 10.2.9. South Korea
- 10.2.9.1. Overview
- 10.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 10.2.9.3. South Korea Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
- 10.2.9.4. South Korea Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 10.2.9.5. South Korea Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
- 10.2.10. Japan
- 10.2.10.1. Overview
- 10.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 10.2.10.3. Japan Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
- 10.2.10.4. Japan Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 10.2.10.5. Japan Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
- 10.2.11. Australia
- 10.2.11.1. Overview
- 10.2.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 10.2.11.3. Australia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
- 10.2.11.4. Australia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 10.2.11.5. Australia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
- 10.2.12. Thailand
- 10.2.12.1. Overview
- 10.2.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 10.2.12.3. Thailand Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
- 10.2.12.4. Thailand Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 10.2.12.5. Thailand Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
- 10.2.13. Indonesia
- 10.2.13.1. Overview
- 10.2.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 10.2.13.3. Indonesia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
- 10.2.13.4. Indonesia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 10.2.13.5. Indonesia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
- 10.2.14. Philippines
- 10.2.14.1. Overview
- 10.2.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 10.2.14.3. Philippines Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
- 10.2.14.4. Philippines Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 10.2.14.5. Philippines Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
- 10.2.15. Malaysia
- 10.2.15.1. Overview
- 10.2.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 10.2.15.3. Malaysia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
- 10.2.15.4. Malaysia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 10.2.15.5. Malaysia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
- 10.2.16. Taiwan
- 10.2.16.1. Overview
- 10.2.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 10.2.16.3. Taiwan Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
- 10.2.16.4. Taiwan Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 10.2.16.5. Taiwan Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
- 10.2.17. Vietnam
- 10.2.17.1. Overview
- 10.2.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 10.2.17.3. Vietnam Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
- 10.2.17.4. Vietnam Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 10.2.17.5. Vietnam Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
- 10.2.18. Hong Kong
- 10.2.18.1. Overview
- 10.2.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 10.2.18.3. Hong Kong Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
- 10.2.18.4. Hong Kong Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 10.2.18.5. Hong Kong Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
- 10.2.19. New Zealand
- 10.2.19.1. Overview
- 10.2.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 10.2.19.3. New Zealand Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
- 10.2.19.4. New Zealand Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 10.2.19.5. New Zealand Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
- 10.2.20. Singapore
- 10.2.20.1. Overview
- 10.2.20.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 10.2.20.3. Singapore Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
- 10.2.20.4. Singapore Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 10.2.20.5. Singapore Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
- 10.2.21. Myanmar
- 10.2.21.1. Overview
- 10.2.21.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 10.2.21.3. Myanmar Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
- 10.2.21.4. Myanmar Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 10.2.21.5. Myanmar Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
- 10.2.22. Rest of APAC
- 10.2.22.1. Overview
- 10.2.22.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 10.2.22.3. Rest of APAC Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
- 10.2.22.4. Rest of APAC Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
- 10.2.22.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
11. Key Vendor Analysis- Asia Pacific Complement-Targeted Therapeutics Industry
- 11.1. Competitive Dashboard
- 11.2. Company Profiles
- 11.2.1. KORU Medical Systems, Inc
- 11.2.2. Vertex Pharmaceuticals
- 11.2.3. Alexion Pharmaceuticals Inc.
- 11.2.4. F. Hoffmann-La Roche Ltd.
- 11.2.5. Creative Biolabs
- 11.2.6. Biogen
- 11.2.7. Allergan
- 11.2.8. Sanofi
- 11.2.9. AbbVie Inc.
- 11.2.10. Merck and Co
- 11.2.11. Pfizer Inc.
- 11.2.12. Dianthus Therapies
- 11.2.13. Others
12. 360 Degree Analyst View
13. Appendix
- 13.1. Research Methodology
- 13.2. References
- 13.3. Abbreviations
- 13.4. Disclaimer
- 13.5. Contact Us
